Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Perjeta Approval Heralds Roche’s Next Wave Of Breast Cancer Drugs

This article was originally published in The Pink Sheet Daily

Executive Summary

Genentech pledges to make new HER2-positive drug Perjeta (pertuzumab) available in the U.S. in two weeks, addresses FDA concerns about production issues and a potential shortage. Firm is already moving forward with plans for integrating Perjeta into its breast cancer portfolio, including combination with antibody-drug conjugate T-DM1.

You may also be interested in...



UnitedHealth Cancer Care Pilot Reduced Overall Costs Despite Higher Drug Spending

The bundled payment pilot program resulted in a 34% decrease in overall cancer treatment costs among participating medical centers despite a 179% increase in drug spending, according to results released July 8.

Oncologists Willing To Embrace pCR, Despite Potential Risks, ASCO Survey Finds

Ahead of Perjeta vote, impromptu survey of clinicians at ASCO Breast Cancer Symposium debate signals readiness to prescribe neoadjuvant drugs, based on pathological complete response data. ASCO President Clifford Hudis cautions of “serious risks to societal well-being with this approach.”

Genentech’s Perjeta Passes Neoadjuvant Pathway Test, FDA Panel Says

Oncologic Drugs Advisory Committee members backing a claim for neoadjuvant treatment of early breast cancer cite pertuzumab’s special circumstances in cautioning that they are not opening the door wide to accelerated approval of other agents under an FDA draft guidance.

Related Content

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

PS074260

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel